Pfizer Inc.and BioNTech SE announced that they have submitted an amended protocol to the U.S. Food and Drug Administration to expand the enrollment of their Phase 3 pivotal COVID-19 vaccine trial to up to approximately 44,000 participants which also allows for the enrollment of new populations.
Enrollment in the trial has been proceeding as planned and the company expects to reach its initial target of up to 30,000 participants next week. The proposed expansion would allow the companies to further increase trial population diversity, and include adolescents as young as 16 years of age and people with chronic, stable HIV (human immunodeficiency viruses), Hepatitis C, or Hepatitis B infection, as well as provide additional safety and efficacy data.
The pivotal trial is event-based and there are many variables that will ultimately impact read-out timing. As stated previously, based on current infection rates, the companies continue to expect that a conclusive readout on efficacy is likely by the end of October.
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
Protein Based Vaccines Examples : The Second Generation Of The COVID-19 Vaccine Is Coming
-
Does Vaccine Protect Against Omicron? Zhang Wenhong : Vaccination Booster Is Still An Effective Tool To Deal With Omicron
-
Are Covid Vaccines Patented ?
-
Several Domestic New Crown Mrna Companies Turn To Developing Broad-Spectrum Vaccines, Exploring Against Different Mutant Strains
-
Unable to get the new crown vaccine for medical reasons What can I do to protect myself?
-
New crown test reagents collected in 18 provinces, fill in the lowest price in the country
-
The battle over the fourth dose of the new crown vaccine
-
Is it necessary to start a fourth dose of the vaccine? The Israeli experience: useful for the elderly
-
How to Test and Use Self-testing COVID-19?
-
7.3 billion doses of COVID-19 vaccine worldwide, half of which are Chinese vaccines
Recommend Reading
-
Install control switches for every protein in living cells
-
Don't be superstitious about high-tech dishwashers
-
Gene Drug Therapy for Myocardial Infarction
-
The First Domestic CAR-T Went Overseas, And The FDA Approved It!
-
China acetone supply glut may continue in July on weak demand
-
Cooperative Intelligent Charging Service of Four Real Estate Developers in China
-
Gabrielle's debut 23 hours has broken 10 million
-
Zhengzhou prohibits the addition of new chemical parks
-
The world's largest tonnage handling robot was born in China
-
Support the rear supply of materials, and participate in the construction